Successful desensitization of methylphenidate-induced rash.
OBJECTIVE
Methylphenidate is a cornerstone of attention-deficit/hyperactivity disorder (ADHD) treatment. Cutaneous adverse reactions resulting from methylphenidate may prohibit its usage. We sought a way to continue this therapy in a patient who developed a rash twice following methylphenidate administration.


METHODS
In a desensitization protocol, methylphenidate was given in increasing doses, 30 minutes apart, over 10 days, until the therapeutic dose was reached and was continued regularly thereafter.


RESULTS
No adverse reactions developed during the desensitization period or during the 6- month follow-up.


CONCLUSIONS
In nonlife threatening cutaneous adverse reactions to methylphenidate, a desensitization protocol may enable the continued, safe administration of this drug.
Confino-Cohen
Ronit
R
Allergy and Clinical Immunology Unit, Meir General Hospital, Kfar Saba, Israel.
Goldberg
Arnon
A
D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000628:therapy*; D005260:Female; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012882:Skin Tests
D000697:Central Nervous System Stimulants; D008774:Methylphenidate